Transcriptional and Posttranscriptional regulation of fibulin-1 by estrogens leads to differential induction of messenger ribonucleic acid variants in ovarian and breast cancer cells

被引:48
作者
Bardin, A
Moll, F
Margueron, R
Delfour, C
Chu, ML
Maudelonde, T
Cavailles, V
Pujol, P
机构
[1] CHU Montpellier, Hop Arnaud Villeneuve, INSERM, U540, F-34095 Montpellier, France
[2] CHU Montpellier, Hop Arnaud Villeneuve, Serv Biol Cellulaire & Hormonale, F-34095 Montpellier, France
[3] Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA
关键词
D O I
10.1210/en.2004-1239
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Fibulin-1 is an extracellular matrix protein overexpressed in epithelial ovarian and breast cancers. In estrogen receptor (ER)-positive ovarian and breast cancer cell lines, fibulin-1 mRNA levels are markedly increased by estrogens. Transfection experiments using fibulin-1 promoter constructs indicate that 17beta-estradiol (E2) increases fibulin-1 gene transcription and that ERalpha is more potent than ERbeta to mediate E2 regulation of the transfected fibulin-1 promoter. Using SL2 cells devoid of specificity protein 1 (Sp1) and site-directed mutagenesis of GC boxes, we evidenced that the E2 regulation occurs through a proximal specificity protein 1 binding site. In addition, we show that fibulin-1C and -1D mRNAs, the two major fibulin-1 splicing variants, are differentially induced by E2. The induction of both mRNAs variants is direct and independent of a newly synthesized protein intermediate. Interestingly, actinomycin D chase experiments demonstrate that E2 treatment selectively shortens the fibulin-1D mRNA half-life. This indicates that estrogens affect differentially the stability of fibulin-1 variants and may explain the lower accumulation of fibulin-1D mRNA on E2 treatment. In conclusion, our data show that estrogens, via ERalpha, are key regulators of fibulin-1 expression at both the transcriptional and post-transcriptional levels. The preferential induction of the fibulin-1C variant, which is overexpressed in ovarian and breast cancer, might play an important role in estrogen-promoted carcinogenesis.
引用
收藏
页码:760 / 768
页数:9
相关论文
共 65 条
[21]   ANALYSIS OF SP1 INVIVO REVEALS MULTIPLE TRANSCRIPTIONAL DOMAINS, INCLUDING A NOVEL GLUTAMINE-RICH ACTIVATION MOTIF [J].
COUREY, AJ ;
TJIAN, R .
CELL, 1988, 55 (05) :887-898
[22]   The fibulin-1 gene (FBLN1) is disrupted in a t(12;22) associated with a complex type of synpolydactyly [J].
Debeer, P ;
Schoenmakers, EFPM ;
Twal, WO ;
Argraves, WS ;
De Smet, L ;
Fryns, JP ;
Van de Ven, WJM .
JOURNAL OF MEDICAL GENETICS, 2002, 39 (02) :98-104
[23]   Functional interactions between the estrogen receptor and the transcription activator Sp1 regulate the estrogen-dependent transcriptional activity of the vitellogenin A1 io promoter [J].
deMedeiros, SRB ;
Krey, G ;
Hihi, AK ;
Wahli, W .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (29) :18250-18260
[24]   Vigilin, a ubiquitous protein with 14 K homology domains, is the estrogen-inducible vitellogenin mRNA 3'-untranslated region-binding protein [J].
Dodson, RE ;
Shapiro, DJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (19) :12249-12252
[25]   Interaction of oncogenic papillomavirus E6 proteins with fibulin-1 [J].
Du, MJ ;
Fan, XL ;
Hong, E ;
Chen, JJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 296 (04) :962-969
[26]   Estrogen replacement therapy and ovarian cancer [J].
Folsom, AR ;
Anderson, JP ;
Ross, JA .
EPIDEMIOLOGY, 2004, 15 (01) :100-104
[27]   Identification of breast cancer-restricted antigens by antibody screening of SKBR3 cDNA library using a preselected patient's serum [J].
Forti, S ;
Scanlan, MJ ;
Invernizzi, A ;
Castiglioni, F ;
Pupa, S ;
Agresti, R ;
Fontanelli, R ;
Morelli, D ;
Old, LJ ;
Pupa, SM ;
Ménard, S .
BREAST CANCER RESEARCH AND TREATMENT, 2002, 73 (03) :245-256
[28]   ESTRADIOL STIMULATES CELL-GROWTH AND SECRETION OF PROCATHEPSIN-D AND A 120-KILODALTON PROTEIN IN THE HUMAN OVARIAN-CANCER CELL-LINE BG-1 [J].
GALTIERDEREURE, F ;
CAPONY, F ;
MAUDELONDE, T ;
ROCHEFORT, H .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1992, 75 (06) :1497-1502
[29]  
GEISINGER KR, 1989, CANCER-AM CANCER SOC, V63, P280, DOI 10.1002/1097-0142(19890115)63:2<280::AID-CNCR2820630213>3.0.CO
[30]  
2-N